IRLAB discovers and develops a portfolio of transformative therapies targeting all stages of Parkinson’s disease. Mesdopetam (IRL790), under development for the treatment of levodopa-induced dyskinesia, has completed Phase IIb and is being prepared for Phase III. Pirepemat (IRL752) is currently in Phase IIb and is being evaluated for its effect on balance and fall frequency in Parkinson’s disease. The pipeline is driven by IRLAB’s proprietary systems biology-based research platform, the Integrative Screening Process (ISP).

IRLAB is listed on Nasdaq Stockholm under the ticker IRLAB A.